Imaging gastrin-releasing peptide receptors (GRPRs) in prostate cancer

Despite significant advances in detection and treatment, prostate cancer (PC) remains the most common malignancy and a major cause of cancer death in men worldwide. Imaging is critically important for the diagnosis, staging, and management of men with prostate cancer (PC). The conventional imaging modalities have been employed for local and metastatic staging with limited performance. Whole-body positron emission tomography (PET) using prostate membrane antigen-based tracers is the most widely used in research and clinical applications in this scenario. However, other ways to image PC are available. Here, we review the clinical literatures on the use of gastrin-releasing peptide receptors (GRPRs) as targets for imaging patients with PC.